Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Don't see it...but I hope you squeeze a few more out of it.
TCBP 7.50 made the list, she should squeeze big soon
https://www.nasdaqtrader.com/trader.aspx?id=regshothreshold
TCBP going back up
I made some money on it yesterday. Trying to make more today
Ain't lookn beastly.
TCBPW: Watch the WARRANTS here exit our Galaxy today!!
break 6s and she will blow up
halt ip up 5.50s
stoploss at 5.02s
Out at 5.
What a nice evening!
Thanks again
TC BioPharm Announces Grant of European Patent Covering Use of Modified Gamma Delta Cells for the Treatment of Cancer and Viral Indications
no problem bro
And there it is! Gratulation.
Thanks
maybe PM or AH
boom coming shortie
Ok thanks!
Will add some in my basket.
back in should get approval European patent the 28 aug
Good to know.
Just on the sideline
sold this turd yesterday 0.92s
PR and price drops
need a pr from the company
European patent GRANTED!
https://register.epo.org/application?number=EP16721208
Thank you so much and good luck$$$
TCBP has had so many price spikes over the month few months it has been a profitable trade to buy after weakness, I have a full position currently.
Do you think it’s time to buy? I am new here
https://stockcharts.com/h-sc/ui?s=tcbp&p=D&yr=0&mn=6&dy=0&id=p38090673899
https://www.barchart.com/stocks/quotes/tcbp/technical-chart?plot=CANDLE&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=1&indicators=BBANDS(20,2);SMA(13);PTP(50);ADX(14);SMA(50);SMACD(12,26,9);RSI(14,100);ACCUM;STOSL(14,3)&sym=CNNA&grid=1&height=500&studyheight=100
https://www.barchart.com/stocks/quotes/tcbp/opinion
https://finance.yahoo.com/quote/tcbp/
Bottom bounce coming!
TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies
TCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies
TCBP: But, nobody interested --- whatever works.
https://stockcharts.com/h-sc/ui?s=tcbp&p=D&yr=0&mn=6&dy=0&id=p38090673899
https://www.barchart.com/stocks/quotes/tcbp/technical-chart?plot=CANDLE&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=1&indicators=BBANDS(20,2);SMA(13);PTP(50);ADX(14);SMA(50);SMACD(12,26,9);RSI(14,100);ACCUM;STOSL(14,3)&sym=CNNA&grid=1&height=500&studyheight=100
https://www.barchart.com/stocks/quotes/tcbp/opinion
https://finance.yahoo.com/quote/tcbp/
Chart bounce candidate!
$TCBP The acceptance of TC BioPharm’s amendment by the MHRA for the ACHIEVE UK trial can be seen as a bullish signal for several reasons:
1. Enhanced Trial Flexibility: The ability to increase the dose level for TCB008 and shift to an outpatient procedure may improve the trial’s efficiency and patient experience. This flexibility could potentially lead to better trial outcomes and patient adherence.
2. Operational Efficiency: Reducing the need for overnight hospital stays for patients after dosing not only improves the quality of life for participants but also eases the burden on clinical sites. This operational efficiency can accelerate the trial’s progress.
3. Positive Regulatory Feedback: Gaining regulatory acceptance for amendments suggests a positive interaction between TC BioPharm and regulatory bodies, indicating that the company is responsive and adaptable to both regulatory requirements and clinical insights.
4. Potential Impact on FDA Trial: The amendments align with the dosing levels of the Investigational New Drug (IND) application for the second cohort, which might streamline the process for the FDA trial. This proactive approach to aligning international trial standards may facilitate smoother regulatory negotiations and trial implementations in multiple jurisdictions.
5. Innovative Treatment Potential: The focus on TCB008 and its application in treating Acute Myeloid Leukemia (AML) underscores TC BioPharm’s commitment to developing innovative cancer treatments. Success in these trials could position the company as a leader in gamma-delta T cell therapies, potentially opening up significant market opportunities.
TCBP..................................https://stockcharts.com/h-sc/ui?s=TCBP&p=W&b=5&g=0&id=p86431144783
Followers
|
14
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
546
|
Created
|
03/02/22
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |